Neurotrophic keratitis: current challenges and future prospects
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Neurotrophic keratitis (NK) is a degenerative corneal disease caused by damage of trigeminal corneal innervation, which leads to spontaneous epithelial breakdown and corneal ulceration. The impairment of corneal sensory innervation causes the reduction of both protective reflexes and trophic neuromodulators that are essential for the vitality, metabolism, and wound healing of ocular surface tissues. A wide range of ocular and systemic conditions, including herpetic keratitis, ocular chemical burns, corneal surgery, diabetes, multiple sclerosis, and neurosurgical procedures, can cause NK by damaging trigeminal innervation. Diagnosis of NK requires careful investigation of any ocular and systemic condition associated with the disease, complete ocular surface examination, and quantitative measurement of corneal sensitivity. The clinical stages of NK range from corneal epithelial alterations (stage 1) to persistent epithelial defect (stage 2) and ulcer (stage 3), which may progress to corneal perforation. Management of NK is based on clinical severity, and the aim of the therapy is to halt the progression of corneal damage and promote epithelial healing. Although several medical and surgical treatments have been proposed, no therapies are currently available to restore corneal sensitivity, and thus, NK remains difficult and challenging to treat. The purpose of this review is to summarize available evidence on the pathogenesis, diagnosis, and treatment of NK. Novel medical and surgical therapies including the topical administration of nerve growth factor and corneal neurotization are also described.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Nerve Growth Factor 35 Years Later
Levi-Montalcini, R. (1987) · Science · doi:10.1126/science.3306916 · Cited by 3,125 · cited 1×
“9 NGF demonstrated a key role in the immune modulation, trophism, and healing of the ocular surface.”
Corneal nerves: structure, contents and function
Müller, L. J., Marfurt, C. F., Kruse, F., & Tervo, T. M. T. (2003) · Experimental Eye Research · doi:10.1016/s0014-4835(03)00050-2 · Cited by 1,220 · cited 2×
“, sub-basal nerve plexus).(4) The great number of sensory nerve endings makes the cornea the most densely innervated tissue in the human body.”
Amniotic Membrane Transplantation for Persistent Epithelial Defects With Ulceration
LEE, S.-H., & TSENG, S. C. G. (1997) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)70125-4 · Cited by 717 · cited 1×
“Amniotic membrane transplantation has been successfully used to treat corneal ulcers and persistent epithelial defects from different causes, including NK. 38,39 The amniotic membrane provides mechanical protection, releases growth factors, and supports epithelial cell adhesion and proliferation.”
Topical Treatment with Nerve Growth Factor for Corneal Neurotrophic Ulcers
Lambiase, A., Rama, P., Bonini, S., Caprioglio, G., & Aloe, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804233381702 · Cited by 420 · cited 1×
“2,51 A recombinant human NGF eye drop formulation has been subsequently developed, and Phase I studies showed a good safety profile.”
Corneal structure and sensitivity in type 1 diabetes mellitus.
Rosenberg, M. E., Tervo, T., Immonen, I. J. R., Müller, L., Grönhagen‐Riska, C., & Vesaluoma, M. H. (2000) · PubMed · Cited by 405
Diagnosis and management of neurotrophic keratitis
Lambiase, A., & Sacchetti, M. (2014) · Clinical Ophthalmology · doi:10.2147/opth.s45921 · Cited by 363 · cited 4×
“12,13 Herpes simplex and herpes zoster eye infections are among the most common conditions leading to corneal anesthesia.”
InfluentialDensity and organization of free nerve endings in the corneal epithelium of the rabbit
Rózsa, A. J., & Beuerman, R. W. (1982) · Pain · doi:10.1016/0304-3959(82)90092-6 · Cited by 359 · cited 1×
“The great number of sensory nerve endings makes the cornea the most densely innervated tissue in the human body.(5) Nerves have a key role in maintaining a healthy ocular surface, both by triggering protective reflexes after injury, and by providing trophic factors to the corneal cells.”
Topical treatment with nerve growth factor for neurotrophic keratitis
Bonini, S. (2000) · Ophthalmology · doi:10.1016/s0161-6420(00)00163-9 · Cited by 320 · cited 1×
“2,51 A recombinant human NGF eye drop formulation has been subsequently developed, and Phase I studies showed a good safety profile.”
Corneal Sensation and Subbasal Nerve Alterations in Patients with Herpes Simplex Keratitis
Hamrah, P., Cruzat, A., Dastjerdi, M. H., Zheng, L., Shahatit, B. M., Bayhan, H. A., Dana, R., & Pavan-Langston, D. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.07.010 · Cited by 293
Amniotic membrane transplantation for severe neurotrophic corneal ulcers
Chen, H.-J. (2000) · British Journal of Ophthalmology · doi:10.1136/bjo.84.8.826 · Cited by 279 · cited 2×
“Amniotic membrane transplantation has been successfully used to treat corneal ulcers and persistent epithelial defects from different causes, including NK. 38,39 The amniotic membrane provides mechanical protection, releases growth factors, and supports epithelial cell adhesion and proliferation.”
Lambìase, A., Manni, L., Bonini, S., Rama, P., Micera, A., & Aloe, L. (2000) · PubMed · Cited by 272
Tavakoli, M., Marshall, A., Pitceathly, R., Fadavi, H., Gow, D., Roberts, M. E., Efron, N., Boulton, A. J., & Malik, R. A. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.08.033 · Cited by 203 · cited 1×
“Recent studies using in vivo confocal microscopy (IVCM) have reported an association between levels of glycated hemoglobin and the density of corneal innervation.(19) Long-term systemic therapy with antipsychotics and antihistamines may also cause NK.”
Nishida, T., Nakamura, M., Ofuji, K., Reid, T. W., Mannis, M. J., & Murphy, C. J. (1996) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199610)169:1<159::aid-jcp16>3.0.co;2-8 · Cited by 185 · cited 1×
“47,48 In two recent studies, patients with epithelial defects associated to NK were treated with eye drops containing a combination of an SP-derived peptide and IGF-1-derived peptide.”
Reinnervation in the cornea after LASIK.
Lee, B. H., McLaren, J. W., Erie, J. C., Hodge, D. O., & Bourne, W. M. (2002) · PubMed · Cited by 174
Yamada, N., Matsuda, R., Morishige, N., Yanai, R., Chikama, T.-I., Nishida, T., Ishimitsu, T., & Kamiya, A. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.130013 · Cited by 138 · cited 1×
“49,50 The treatment induced the healing of the epithelial defects in 89% 49 and 73% of cases 50 without any adverse side effect.”
Nishida, T., Chikama, T.-I., Morishige, N., Yanai, R., Yamada, N., & Saito, J. (2007) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-007-0480-z · Cited by 95 · cited 1×
“49,50 The treatment induced the healing of the epithelial defects in 89% 49 and 73% of cases 50 without any adverse side effect.”
Nakamura, M., Ofuji, K., Chikama, T.-I., & Nishida, T. (1997) · Current Eye Research · doi:10.1076/ceyr.16.3.275.15409 · Cited by 93 · cited 1×
“47,48 In two recent studies, patients with epithelial defects associated to NK were treated with eye drops containing a combination of an SP-derived peptide and IGF-1-derived peptide.”
Rouet, V., Hamma‐Kourbali, Y., Petit, E., Panagopoulou, P., Katsoris, P., Barritault, D., Caruelle, J. P., & Courty, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504492200 · Cited by 89
Ferrari, M. P., Mantelli, F., Sacchetti, M., Antonangeli, M. I., Cattani, F., D’Anniballe, G., Sinigaglia, F., Ruffini, P. A., & Lambìase, A. (2013) · BioDrugs · doi:10.1007/s40259-013-0079-5 · Cited by 78 · cited 1×
“A recombinant human NGF eye drop formulation has been subsequently developed, and Phase I studies showed a good safety profile.(52) Phase II trials are currently ongoing to evaluate the efficacy of two different formulations of this treatment in patients with NK stage 2 and 3 (NCT02227147, NCT01756456).”
Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin β4
Dunn, S. P., Heidemann, D. G., Chow, C. Y. C., Crockford, D., Turjman, N. A., Angel, J., Allan, C. B., & Sosne, G. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05471.x · Cited by 75
Alper, M. G. (1975) · Europe PMC (PubMed Central) · Cited by 65
Treatment of Chronic Nonhealing Neurotrophic Corneal Epithelial Defects With Thymosin Beta 4
Dunn, S. P., Heidemann, D. G., Chow, C., Crockford, D. N., Turjman, N. A., Angel, J., Allan, C. B., & Sosne, G. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.53 · Cited by 60
The Nerve Growth Factor 35 Years Later
Levi‐Montalcini, R. (1997) · World Scientific series in 20th century biology · doi:10.1142/9789812830319_0031 · Cited by 47
Versura, P., Buzzi, M., Giannaccare, G., Terzi, A., Fresina, M., Velati, C., & Campos, E. C. (2016) · PubMed · doi:10.2450/2015.0020-15 · Cited by 47 · cited 1×
“30,31 It has been shown that umbilical cord blood serum eye drops is effective in treating NK, achieving a complete corneal healing in all the patients under study.”
Self-citationGiannaccare, G., Buzzi, M., Fresina, M., Velati, C., & Versura, P. (2017) · Cornea · doi:10.1097/ico.0000000000001257 · Cited by 44
Self-citation
Cited by
Okada, Y., Zhang, Y., Zhang, L., Yeh, L.-K., Wang, Y.-C., Saika, S., & Liu, C.-Y. (2020) · Laboratory Investigation · doi:10.1038/s41374-019-0338-2 · Cited by 13
Metadata
- Authors
- Versura, P., Giannaccare, G., Pellegrini, M., Sebastiani, S., & Campos, E. C.
- Venue
- Eye and Brain
- Publisher
- Informa UK Limited
- Published
- 2018-06
- Volume
- Volume 10
- Pages
- 37-45
- ISSN
- 1179-2744 (ISSN-L)
- OpenAlex
- W2809869172
- Cited by
- 178
- References
- 25
- FWCI
- 9.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.